PEOPLE - Bioheart (US) makes appointments:
This article was originally published in Clinica
Bioheart (Weston, Florida), a discoverer, developer and commercialiser of cellular-based products, has strengthened its management team with several new appointments, three of whom, Manny Villafana, Richard Spencer and Norman Dann, have been appointed to the board. Mr Villafana is a former executive of Medtronic and founder of Cardiac Pacemakers (now part of Guidant CRM), St Jude Medical and ATS Medical. Mr Spencer, is the former president of the marketing division of Cordis (now Cordis Johnson & Johnson) and vice-president of Cordis Dow, will also serve as a consultant to Bioheart. Mr Dann, who has over 40 years of industry experience, is a former board member, director and consultant for World Medical Manufacturing Corporation (now Medtronic AVE World Medical).
You may also be interested in...
After two Indian vaccine makers, Serum Institute of India and Cadila Healthcare joined the fight against COVID-19, Bharat Biotech may follow suit. Others like Hilleman have decided against it for the moment while Panacea Biotech is weighing the pros and cons of developing a SARS-CoV-2 vaccine after a sour experience with H1N1.
South Korea’s HLB has begun a new growth phase by taking over US-based clinical stage biotech firm Immunomic Therapeutics. Through the acquisition, it is poised to add new pipeline assets including a Phase II vaccine therapy for glioblastoma and proprietary lysosomal targeting technology.
Less-invasive technologies to treat benign prostatic hyperplasia are fast becoming viable alternatives to medication and surgery. Here's what one researcher in the area, Steven Raman, had to say about the new options.